First Clinical Experience of Jarvik 2015 in North America: The New Era of Pediatric-Specific VAD Support

2019 ◽  
Vol 38 (4) ◽  
pp. S181
Author(s):  
I. Adachi ◽  
J.A. Spinner ◽  
Z. Spigel ◽  
H. Tunuguntla ◽  
B. Elias ◽  
...  
Keyword(s):  
North America ◽  
Clinical Experience ◽  
New Era

Strangers on the Land

2020 ◽  
pp. 37-62
Author(s):  
Ryan Hall
Keyword(s):  
North America ◽  
Native People ◽  
Intermountain West ◽  
Hudson's Bay Company ◽  
New Era ◽  
North West ◽  
Canadian North ◽  
Direct Trade ◽  
First Time ◽  
Hudson’S Bay Company

This chapter describes the period from 1781 until 1806. Following a devastating smallpox epidemic in 1781, the Blackfoot established direct trade with non-Native people for the first time, circumventing middlemen who had been devastated by the disease. While many embraced the opportunities for trade, they also carefully structured their relationships with newcomers, repurposing regional traditions of peaceful exchange and ceremony for a new era. At the same time, they deliberately prevented British (Hudson’s Bay Company) and Canadian (North West Company) traders from expanding their trade into new regions, especially the intermountain West, thus securing crucial advantages over their western and southern neighbors. By 1806, Blackfoot people had become one of the most powerful and expansive Indigenous polities in North America.

Use of the Intubating LMA-Fastrach™  in 254 Patients with Difficult-to-manage Airways

2001 ◽  
Vol 95 (5) ◽  
pp. 1175-1181 ◽  
Author(s):  
David Z. Ferson ◽  
William H. Rosenblatt ◽  
Mary J. Johansen ◽  
Irene Osborn ◽  
Andranik Ovassapian
Keyword(s):  
Radiation Therapy ◽  
North America ◽  
Clinical Experience ◽  
Medical Records ◽  
San Diego ◽  
Success Rates ◽  
Lehane Grade ◽  
Different Types ◽  
Elective Treatment ◽  
Established Role

Background The laryngeal mask airway (LMA; LMA North America, Inc., San Diego, CA) has a well-established role in the emergency and elective treatment of patients with difficult-to-manage airways (DA). In this study, the authors report their clinical experience with the intubating LMA (LMA-Fastrach; LMA North America, Inc., San Diego, CA) in 254 patients with different types of DA. Methods The authors reviewed the anesthetic and medical records of patients with DA in whom the LMA-Fastrach was used electively or emergently at four institutions from October 1997 through October 2000. In each case, the number of insertion and intubation attempts was recorded. Success rates for blind and fiber optically guided intubation through the LMA-Fastrach were calculated, up to a maximum of five attempts per patient. Results The LMA-Fastrach was used in 257 procedures performed in 254 patients with DA, including patients with Cormack-Lehane grade 4 views; patients with immobilized cervical spines; patients with airways distorted by tumors, surgery, or radiation therapy; and patients wearing stereotactic frames. Insertion of the LMA-Fastrach was accomplished in three attempts or fewer in all patients. The overall success rates for blind and fiber optically guided intubations through the LMA-Fastrach were 96.5% and 100.0%, respectively. Conclusions The LMA-Fastrach was used successfully in a high percentage of patients who presented with a variety of DA. The clinical experience presented herein indicates that this device may be particularly useful in the emergency and elective treatment of patients in whom intubation with a rigid laryngoscope has failed and in the treatment of patients with immobilized cervical spines.

Biocompatibility of New Peritoneal Dialysis Solutions: Clinical Experience

2000 ◽  
Vol 20 (5_suppl) ◽  
pp. 48-56 ◽  
Author(s):  
Elvia Garcia–Lopez ◽  
Bengt Lindholm ◽  
Anders Tranæus
Keyword(s):  
Peritoneal Dialysis ◽  
Clinical Experience ◽  
Degradation Products ◽  
Peritoneal Membrane ◽  
Negative Effects ◽  
New Era ◽  
Combined Use ◽  
Osmotic Agent ◽  
High Concentrations ◽  
Conventional Solution

The successful development of peritoneal dialysis (PD) during the last two decades has been made possible by using well-established glucose-based solutions with lactate as buffer. On the other hand, awareness has been increasing about the potentially negative effects of the high concentrations of glucose and lactate, and the low pH of conventional PD solutions. This awareness has prompted an intensive effort to search for and test alternative solutions. As a result, three new, more biocompatible solutions— containing either less glucose or less lactate—are available. Amino acid–based solution uses amino acids instead of glucose as the osmotic agent; it is indicated for treatment of malnutrition. The higher pH and absence of glucose in this solution may prevent alterations of the peritoneal membrane caused by acidity and high glucose concentrations. Bicarbonate/lactate–buffered solution contains a physiologic concentration of bicarbonate and a reduced concentration of lactate; it also has a physiologic pH and markedly reduced levels of glucose degradation products (GDPs). Icodextrin-based solution contains icodextrin as the osmotic agent; it is indicated for long dwells, delivering sustained ultrafiltration for more than 16 hours. This iso-osmolar glucose-free solution may reduce peritoneal membrane alterations caused by glucose or the hyperosmolality (or both) of conventional solutions. Clinical experience of the new solutions is now extensive, and their efficacy and safety are well documented. It therefore seems appropriate to state that we have entered a new era of PD therapy. Each of the new solutions may be less damaging to the peritoneal membrane than conventional solution. In addition, they permit better management of malnutrition and fluid status, and may thus help to improve PD patient survival. Although the effects of each of these new solutions have been well described, clinical documentation of the combined use of these new biocompatible PD solutions is still insufficient. However, the results of studies are expected, during the coming years, to support the combined use of the new solutions as the preferred standard practice for PD.

The Beginning of a New Era in Tissue Expansion: Self-Filling Osmotic Tissue Expander???Four-Year Clinical Experience

2004 ◽  
pp. 1025-1031 ◽  
Author(s):  
Marc Alexander Ronert ◽  
Holger Hofheinz ◽  
Eduoard Manassa ◽  
Hutan Asgarouladi ◽  
Rolf R??diger Olbrisch
Keyword(s):  
Clinical Experience ◽  
Tissue Expander ◽  
Tissue Expansion ◽  
New Era

Powder and Rouge

2017 ◽  
Author(s):  
Nancy Yunhwa Rao
Keyword(s):  
United States ◽  
Nineteenth Century ◽  
North America ◽  
Late Nineteenth Century ◽  
New Era ◽  
Chinese Opera ◽  
Cantonese Opera ◽  
Late Nineteenth

This chapter shifts our focus to the thriving community of Cantonese opera theaters in Canada, from as early as the late nineteenth century. Despite anti-Chinese initiatives growing toward the end of the century, Chinese opera performers were admitted into Canada with regularity, and Chinese theaters continued to find success. Beginning with the troupes, popular performers and theaters of the 1910s, the chapter traces the trajectories of their performing circuit and theaters into the 1920s. In particular, the 1921 opening of Le Wannian theater in Vancouver marked the beginning of a new era, whose performers, such as Guan Yinglian, had an enormous impact on the community. Finally, the Victoria/Vancouver-based Lun On company led Cantonese opera troupe to return to United States, which in turn commenced the golden era of Cantonese opera in North America. The chapter concludes with a discussion of the significance of Triangle Route between Victoria, Vancouver and Seattle.

Sign in / Sign up

Export Citation Format

Share Document